Our project leader Gill Farrar will be presenting AMYPAD at the Alzheimer Europe Conference (#30AEC) as part of the Neuronet session entitled “Regulatory & HTA assessment: a critical step in delivering innovation for patient benefit”.
The conference will be hosted online from 20 to 22 October 2020, under the banner “Dementia in a Changing World”. Online registration is open until 19 October 2020.
The session “Regulatory and HTA assessment: a critical step in delivering innovation for patient benefit” will be held on 21 October at 14:15-15:30 CET. This P15 session includes four talks:
- A framework for regulatory and health technology assessment engagement in neurodegenerative disease research (Diana O’Rourke – NICE, United Kingdom)
- ROADMAP: regulatory and health technology assessment considerations for new Alzheimer’s disease drugs (Jacoline Bouvy – Nice, United Kingdom)
- AMYPAD: Lessons and reflections from Regulatory and HTA Interactions (Gill Farrar – GE Healthcare, United Kingdom)
- The Mobilise-D consortium regulatory strategy for qualification of wearable sensors to quantify mobility in drug trials (Marco Viceconti – Alma Mater Studiorum – University of Bologna, Italy)